Last $169.14 USD
Change Today -0.15 / -0.09%
Volume 839.8K
ALXN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 09/2/14 All times are local (Market data is delayed by at least 15 minutes).

alexion pharmaceuticals inc (ALXN) Snapshot

Open
$169.99
Previous Close
$169.29
Day High
$170.45
Day Low
$168.42
52 Week High
02/25/14 - $185.43
52 Week Low
10/22/13 - $100.89
Market Cap
33.5B
Average Volume 10 Days
768.4K
EPS TTM
$2.15
Shares Outstanding
197.8M
EX-Date
--
P/E TM
78.7x
Dividend
--
Dividend Yield
--
Current Stock Chart for ALEXION PHARMACEUTICALS INC (ALXN)

alexion pharmaceuticals inc (ALXN) Related Businessweek News

View More BusinessWeek News

alexion pharmaceuticals inc (ALXN) Details

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trials for its usage for the treatment of PNH pediatric trial, presensitized renal transplant, delayed kidney transplant graft function, hemolytic uremic syndrome, neuromyelitis optica, myasthenia gravis, and cold agglutinin disease. In addition, it develops Asfotase alfa that is under Phase II clinical trial for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; ALXN 1007, a novel humanized antibody for treating inflammatory disorders; and cPMP that is in Phase I trial for treating metabolic disorders. The company primarily serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies. Alexion Pharmaceuticals, Inc. has a strategic agreement with Moderna Therapeutics, Inc. for the development of messenger RNA therapeutics to treat rare diseases. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.

1,774 Employees
Last Reported Date: 02/10/14
Founded in 1992

alexion pharmaceuticals inc (ALXN) Top Compensated Officers

Co-Founder, Chief Executive Officer, Treasure...
Total Annual Compensation: $1.2M
Co-Founder, Chief Global Operations Officer a...
Total Annual Compensation: $607.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $615.0K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $610.0K
Global Head of Research & Development and Exe...
Total Annual Compensation: $547.0K
Compensation as of Fiscal Year 2013.

alexion pharmaceuticals inc (ALXN) Key Developments

Alexion Pharmaceuticals, Inc. Initiates Multinational Registration Trial of Eculizumab for Prevention of Delayed Graft Function (DGF) After Kidney Transplantation

Alexion Pharmaceuticals, Inc. announced the initiation of dosing in a single, multinational, placebo-controlled clinical trial to evaluate the efficacy and safety of eculizumab (Soliris(R)) for the prevention of delayed graft function (DGF) after kidney transplantation in adult patients who are at increased risk of DGF. DGF is an early and serious complication of organ transplantation that affects approximately 25%, and possibly up to 50%, of deceased-donor kidney transplant cases, and is characterized by the failure of a transplanted organ to function normally immediately following transplantation. Patients experiencing DGF after a kidney transplant require dialysis in order to survive. Worldwide, there is an unmet medical need for a highly innovative therapy for patients at high risk of developing DGF, as there are no approved treatments to prevent DGF after kidney transplantation. In most cases DGF results from ischemia/reperfusion injury (IRI). IRI is due to multiple processes that occur following the restoration of blood flow to an area that had previously experienced deficient blood flow. Uncontrolled complement activation following IRI is believed to play a major role in the development of DGF. Soliris is currently approved in nearly 50 countries for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and in nearly 40 countries for the treatment of atypical hemolytic uremic syndrome (aHUS), two debilitating, ultra-rare and life-threatening disorders caused by chronic uncontrolled complement activation. Soliris is not approved in any country for the prevention of DGF after kidney transplantation.

Alexion's Soliris (Eculizumab) Receives Orphan Drug Designation for the Treatment of Myasthenia Gravis

Alexion Pharmaceuticals announced that the European Commission has granted orphan drug designation (ODD) to Soliris(R) (eculizumab) for the treatment of patients with Myasthenia Gravis (MG), a rare, debilitating neurologic disorder caused by uncontrolled complement activation. In patients with MG, uncontrolled complement activation due to antibodies directed at the neuromuscular junction can ultimately lead to profound and debilitating weakness of various muscle groups throughout the body. Soliris is a first-in-class terminal complement inhibitor and is currently approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two debilitating, ultra-rare and life-threatening disorders caused by chronic uncontrolled complement activation. Soliris is not approved in any country to treat MG. Alexion is enrolling patients in a multinational, placebo-controlled registration trial of eculizumab in patients with refractory generalized MG. The European Commission grants orphan medicinal product status to provide incentives to develop medicinal products to treat, prevent or diagnose diseases or conditions that affect no more than five in 10,000 persons in the EU. The orphan medicinal product status designation would provide Alexion with certain benefits and incentives in the EU, including a period of market exclusivity if Soliris is ultimately approved for the designated indication.

Alexion Pharmaceuticals, Inc. Announces Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2014; Revised Earnings Guidance for 2014

Alexion Pharmaceuticals, Inc. announced unaudited consolidated financial results for the second quarter and six months ended June 30, 2014. The company reported non-GAAP net income of $229.1 million, or $1.12 per diluted share, in the second quarter of 2014, compared to non-GAAP net income of $147.2 million, or $0.73 per diluted share, in the second quarter of 2013. The company reported GAAP net income of $166.5 million, or $0.83 per diluted share, in the second quarter of 2014, compared to GAAP net income of $95.9 million, or $0.48 per diluted share, in the second quarter of 2013. Net product sales was $512,495,000, compared to $370,091,000 for the last year. Operating income was $218,849,000, compared to $137,691,000 for the last year. Income before income taxes was $218,646,000, compared to $137,263,000 for the last year. This increase in revenue reflected an unfavorable foreign exchange impact of one percent. Revenue performance for the quarter reflected steady additions of new patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) commencing Soliris treatment. For the six months, the company reported net product sales of $1,079,111,000, compared to $709,032,000 for the last year. Operating income was $428,352,000, compared to $254,663,000 for the last year. Income before income taxes was $430,557,000, compared to $254,004,000 for the last year. Net income was $325,849,000 or $1.62 per diluted share, compared to $178,102,000 or $0.90 per diluted share for the last year. Non-GAAP net income was $541,671,000 or $2.65 per diluted share, compared to $278,544,000 or $1.38 per diluted share for the last year. The company announced that it is revising upward its revenue guidance for 2014 from the previous range of $2.15 to $2.17 billion, now to the higher range of $2.18 to $2.20 billion. Non-GAAP earnings per share is also being revised upward, from the previous range of $4.75 to $4.85, now to the higher range of $4.95 to $5.05 per share. The company is reiterating the other elements of its 2014 financial guidance also.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALXN:US $169.14 USD -0.15

ALXN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Illumina Inc $179.73 USD +0.37
Regeneron Pharmaceuticals Inc $359.50 USD +9.05
Sigma-Aldrich Corp $103.99 USD -0.01
UCB SA €72.62 EUR -0.81
Vertex Pharmaceuticals Inc $92.96 USD -0.61
View Industry Companies
 

Industry Analysis

ALXN

Industry Average

Valuation ALXN Industry Range
Price/Earnings 85.2x
Price/Sales 17.4x
Price/Book 11.6x
Price/Cash Flow 83.5x
TEV/Sales 16.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALEXION PHARMACEUTICALS INC, please visit www.alexionpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.